Evaluation of bone marrow microenvironment could change how myelodysplastic syndromes are diagnosed and treated

Cytometry A. 2018 Jul;93(9):916-928. doi: 10.1002/cyto.a.23506. Epub 2018 Sep 13.

Abstract

Myelodysplastic syndromes are a heterogeneous group of clonal hematopoietic disorders. However, the therapies used against the hematopoietic stem cells clones have limited efficacy; they slow the evolution toward acute myeloid leukemia rather than stop clonal evolution and eradicate the disease. The progress made in recent years regarding the role of the bone marrow microenvironment in disease evolution may contribute to progress in this area. This review presents the recent updates on the role of the bone marrow microenvironment in myelodysplastic syndromes pathogenesis and tries to find answers regarding how this information could improve myelodysplastic syndromes diagnosis and therapy.

Keywords: bone marrow microenvironment; flow-cytometry; mesenchymal stromal cells; myelodysplastic syndromes.

Publication types

  • Review

MeSH terms

  • Animals
  • Bone Marrow / pathology*
  • Cellular Microenvironment / physiology*
  • Hematopoietic Stem Cells / pathology
  • Humans
  • Myelodysplastic Syndromes / pathology*